NCT00839956已完成2 期
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant for Multiple Myeloma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 31
- 试验地点
- 1
- 主要终点
- Toxicity as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0
研究概览
简要总结
This phase II trial studies the side effects of giving bortezomib together with vorinostat and to see how well it works in treating patients with multiple myeloma who have undergone autologous stem cell transplant. Bortezomib and vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with vorinostat after an autologous stem cell transplant may stop the growth of any cancer cells that remain after transplant.
详细描述
PRIMARY OBJECTIVES:
I. Evaluate the toxicity of the use of vorinostat and bortezomib as maintenance therapy after autologous transplant.
SECONDARY OBJECTIVES:
I. Evaluate the median time to disease progression.
II. Evaluate survival.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Any autologous patient who underwent high dose melphalan (>= 140 mg/m^2) therapy or peripheral blood stem cell (PBSC) rescue for any stage of multiple myeloma and did not participate in another clinical transplant trial whose primary endpoint is also evaluating long-term, disease-free survival, or survival
- •Platelet count (transfusion independent) > 75,000 cells/mm^3 and absolute granulocyte count > 1500 cells/mm^3 for 5 calendar days after recovery from high dose therapy
- •Consenting for study between 30 days to 120 days after transplant
- •Female patient of childbearing potential has a negative serum pregnancy test beta-hCG within 72 hours prior to receiving the first dose of vorinostat
- •Female patient is either post-menopausal, free from menses for >= 2 years, surgically sterilized, or willing to use 2 adequate barrier methods of contraception to prevent pregnancy or agrees to abstain from heterosexual activity throughout the treatment on study, starting with visit 1 and for 3 months afterward
- •Male patient agrees to use an adequate method of contraception for the duration of the treatment on study and for 3 months afterward
排除标准
- •Eastern Cooperative Oncology Group (ECOG) performance status >= 2
- •A left ventricular ejection fraction less than 45% pre-transplant
- •Congestive heart disease with transplant, history of myocardial infarction (MI), history of coronary artery disease, or prolonged corrected QT interval (QTC)
- •Total bilirubin greater than 2 mg/ml (unless history of Gilbert's disease)
- •Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) > 2.5 x upper limit of normal (ULN)
- •Creatinine clearance < 20 ml/minute, calculated by Cockroft-Gault formula or measured urine
- •Cannot give informed consent
- •Untreated systemic infection
- •Poorly-controlled diabetes mellitus (DM)
- •>= grade 3 peripheral neuropathy
- •Prior history of human immunodeficiency virus (HIV) positivity with pre-transplant evaluation or known history of hepatitis B or C
- •Previous history of hypersensitivity to Bortezomib, boron, or mannitol; known hypersensitivity to the components of study drug or its analogs
- •Require therapeutic anticoagulation treatment, especially with coumadin
- •Potassium (K) and magnesium (Mg) < normal limits
- •Patient who has had chemotherapy, radiotherapy, or biological therapy, within 30 days (42 days for nitrosoureas or mitomycin C) prior to initial dosing with study drug(s) or who has not recovered from adverse events due to agents administered more than 30 days earlier; patients who have received localized consolidation radiation to bone only less than 30 days prior to study entry are allowed
- •Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of initial dosing with study drugs
- •Patient had prior treatment with an histone deacetylase inhibitor (HDAC) inhibitor (e.g., romidespin [depsipeptide], NSC-630176, MS 275, LAQ-824, belinostat [PXD-101], LBH589, MGCD0103, CRA024781, etc.)
- •Patients who have received compounds with HDAC inhibitor-like activity, such as valproic acid, as anti-tumor therapy should not enroll in this study
- •Patients who have received such compounds for other indications, e.g. valproic acid for epilepsy, may enroll after a 30-day washout period
- •History of central nervous system (CNS) disease
- •Symptomatic ascites or pleural effusions
- •Patient has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
- •Patient is, at the time of signing informed consent, a regular user (including "recreational use") of any illicit drugs, substance abuse or had a recent history (within the last year) of drug or alcohol abuse
- •Patient is pregnant or breast-feeding, or expecting to conceive or father children within the projected duration of the study
- •Patient with a history of a prior malignancy with the exception of cervical intraepithelial neoplasia; non-melanoma skin cancer; adequately treated localized prostate carcinoma with prostate-specific antigen (PSA) < 1.0; or who has undergone potentially curative therapy with no evidence of disease for five years, and/or who is deemed at low risk for recurrence by his/her treating physician
- •Patient has a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study or is not in the best interest of the patient to participate
- •Patient has a history of a gastrointestinal surgery or other procedures that might, in the opinion of the investigator, interfere with the absorption or swallowing of the study drugs
研究组 & 干预措施
Treatment (enzyme inhibitor therapy)
Experimental
Patients receive bortezomib IV on days 2 and 5 and vorinostat PO QD on days 1-14. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
干预措施: Vorinostat (Drug)
Treatment (enzyme inhibitor therapy)
Experimental
Patients receive bortezomib IV on days 2 and 5 and vorinostat PO QD on days 1-14. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
干预措施: Bortezomib (Drug)
结局指标
主要结局
Toxicity as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0
时间窗: The first three months of therapy
The first three months of therapy will be used as the time period in which toxicity will be evaluated and stopping rules for unacceptable toxicity will be implemented. Rules for stopping the study will be based on the rate of withdrawal due to significant toxicity (grade IV, non-hematological, non-metabolic, nonperipheral neuropathy).
次要结局
- Survival for All Patients(Up to 5 years)
- Median Follow-up Survival for All Patients(Up to 5 years)
- Time to Disease Progression in Patients Who Progressed(Up to 5 years)
研究者
Leona Holmberg
Principal Investigator
Fred Hutchinson Cancer Center
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin LymphomaAdult Diffuse Large B-Cell LymphomaB-Cell Non-Hodgkin LymphomaNon-Hodgkin LymphomaT-Cell Non-Hodgkin LymphomaMantle Cell LymphomaFollicular LymphomaNCT00992446Fred Hutchinson Cancer Center27
已完成
2 期
Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma MultiformeAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain TumorNCT00641706National Cancer Institute (NCI)44
终止
2 期
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic MalignanciesMixed Lineage Acute LeukemiaAcute Lymphoid LeukemiaAcute Myeloid LeukemiaNCT02419755St. Jude Children's Research Hospital12
已完成
1 期
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and LymphomaChildhood Burkitt LymphomaChildhood Central Nervous System ChoriocarcinomaChildhood Central Nervous System Germ Cell TumorChildhood Central Nervous System GerminomaChildhood Central Nervous System Mixed Germ Cell TumorChildhood Central Nervous System TeratomaChildhood Central Nervous System Yolk Sac TumorChildhood Choroid Plexus TumorChildhood CraniopharyngiomaChildhood Diffuse Large Cell LymphomaChildhood Immunoblastic Large Cell LymphomaChildhood MedulloepitheliomaChildhood MeningiomaChildhood Mixed GliomaChildhood Nasal Type Extranodal NK/T-cell LymphomaChildhood OligodendrogliomaRecurrent Childhood Anaplastic Large Cell LymphomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Central Nervous System Embryonal TumorRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood Grade III Lymphomatoid GranulomatosisRecurrent Childhood Large Cell LymphomaRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood Malignant Germ Cell TumorRecurrent Childhood MedulloblastomaRecurrent Childhood PineoblastomaRecurrent Childhood Small Noncleaved Cell LymphomaRecurrent Childhood Subependymal Giant Cell AstrocytomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway and Hypothalamic GliomaRecurrent Childhood Visual Pathway GliomaRecurrent/Refractory Childhood Hodgkin LymphomaUnspecified Childhood Solid Tumor, Protocol SpecificNCT00994500National Cancer Institute (NCI)20
已完成
3 期
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)Multiple MyelomaNCT00773747Merck Sharp & Dohme LLC637